Biolight has obtained Medical Device Registration Certificates issued by the National Medical Products Administration for its blood purification devices Elix-Ω and Elix-90. These are Class III medical devices indicated for various blood purification therapies in adult patients, with registration valid until July 15, 2031. In the first quarter of 2026, Biolight recorded revenue of 243 million yuan and a net loss attributable to the parent company of 7.32 million yuan.
Guangdong Biolight Meditech Co LtdBiolight obtained medical device registration certificates for its blood purification devices, enabling market access.